Cancer discovery
-
Axitinib plus pembrolizumab has a 73% response rate in previously untreated advanced renal cell carcinoma.
-
The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test.
-
Wild-type KRAS increases survival and resistance to MEK inhibitors in KRAS-mutant lung cancer cells.
-
The BCL2 inhibitor venetoclax is approved in the United States for only a subset of patients with refractory chronic lymphocytic leukemia. However, in light of data presented at the American Society of Hematology 2017 Annual Meeting, clinicians are thinking ahead to administering the drug more broadly-in combinations and as a first-line therapy-for other patients with the disease.